3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Multiple Myeloma
2
Carcinoma in Situ
2
Vulvar Neoplasms
1
Vulvar Diseases
1
Uterine Cervical Neoplasms
1
Uterine Cervical Dysplasia
1
Urinary Bladder Neoplasms
1
Rectal Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Papillomavirus Infections
1
Oropharyngeal Neoplasms
1
Lymphoma, Follicular
1
Leukemia, Hairy Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma
1
Burkitt Lymphoma
1
Anus Neoplasms
1
Interventions
pembrolizumab
128
Carboplatin
126
Pemetrexed
106
Cisplatin
79
Paclitaxel
60
osimertinib
54
Nivolumab
53
Docetaxel
52
durvalumab
48
Specimen Handling
40
Magnetic Resonance Spectroscopy
36
Gemcitabine
36
Radiosurgery
29
atezolizumab
27
130-nm albumin-bound paclitaxel
27
Cetuximab
26
Radiotherapy
23
Ipilimumab
22
Drug Therapy
22
cemiplimab
20
Bevacizumab
20
amivantamab
18
Taxes
16
Ramucirumab
13
tislelizumab
12
alectinib
12
Radiation
12
Biopsy
12
lazertinib
11
Oxaliplatin
11
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Non-Small-Cell Lung
×
Diphenhydramine
×
90 days
×
Clear all
NCT04165096
2026-05-13
MK-3475-01C
Merck Sharp & Dohme LLC
Phase 2
Completed
128 enrolled
14 charts